Extended Data Fig. 3: UA treatment reduces LASP/LP cell proportion with concordance between scRNAseq and flow cytometry.
From: Anti-progestin therapy targets hallmarks of breast cancer risk
A) Percentage of LASP, LHS and BMYO cell populations determined by scRNAseq in 6 pairs of tissue before (baseline) and after (post-treatment) UA therapy. B) Correlation (two-sided test) between the percentage of LP cells determined by flow cytometry and LASP cells determined by scRNAseq. N = 6 tissue pairs. C-D) Cell subcluster proportionality fold change (post-treatment / baseline) across all subcluster cell types (C) and with proportionality restricted to epithelial cell types (D). Positive (negative) changes denote subcluster enrichment (depletion) in samples after UA therapy. Box plots centre lines represent median values, box bounds indicate the 25th and 75th percentiles, and whiskers extend to the most extreme datapoint within 1.5 × IQR (inter-quartile range) of the outer hinge of the boxplot. N = 6 tissue pairs.
